These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27548441)

  • 1. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
    Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel drugs in clinical development for hepatocellular carcinoma.
    Waidmann O; Trojan J
    Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
    Hollebecque A; Malka D; Ferté C; Ducreux M; Boige V
    Eur J Cancer; 2015 Feb; 51(3):327-39. PubMed ID: 25559615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
    Villanueva A
    J Hepatol; 2013 Aug; 59(2):392-5. PubMed ID: 23548196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
    Lee SJ; Lim HY
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):191-200. PubMed ID: 28506080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: from literature to clinical practice.
    Di Marco V; De Vita F; Koskinas J; Semela D; Toniutto P; Verslype C
    Ann Oncol; 2013 Apr; 24 Suppl 2():ii30-7. PubMed ID: 23715941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
    Tovoli F; Lorenzo S; Barbera MA; Garajova I; Frega G; Palloni A; Pantaleo MA; Biasco G; Brandi G
    Future Oncol; 2017 Sep; 13(21):1893-1905. PubMed ID: 28693355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathways and targets in hepatocellular carcinoma.
    Psyrri A; Arkadopoulos N; Vassilakopoulou M; Smyrniotis V; Dimitriadis G
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 13. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.
    Llovet JM; Hernandez-Gea V
    Clin Cancer Res; 2014 Apr; 20(8):2072-9. PubMed ID: 24589894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.
    Germano D; Tinessa V; Barletta E; Cannella L; Daniele B
    Drugs Aging; 2013 Nov; 30(11):887-92. PubMed ID: 24097332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
    Woo HY; Yoo SY; Heo J
    Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
    Dekervel J; van Pelt J; Verslype C
    Curr Opin Oncol; 2013 Jul; 25(4):409-16. PubMed ID: 23680714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
    Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
    Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.